Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Charles River Laboratories Announces Third-Quarter 2022 Results
November 2, 2022 7:00 AM EDTThird-Quarter Revenue of $989.2 Million
Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63
Narrows 2022 Revenue Growth and Earnings Per Share Guidance
Announces Planned Divestiture of Avian Vaccine Business
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2022. For the quarter, revenue was $989.2 million, an increase of 10.4% from $895.9 million in the third quarter of 2021.
Acquisitions contributed 1.7% to consolidated third-quarter revenue growth. The... More
